Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Chaundre Cross

Radiation Oncology Naples, FL Medical Doctor

NPI 1972506707 CMS profile 180617

1885 Sw Health Pkwy, Naples, FL 34109

Open in the dashboard

General payments

$131,131

227 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Chaundre Cross of Naples, FL is reported in the CMS Open Payments database as having received $131,131 across 227 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $13,101 34
2021 General $59,587 81
2020 General $37,122 65
2019 General $21,322 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chaundre Cross
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Chaundre Cross were reported at $0. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Chaundre Cross Radiation Oncology median Middle half National median
2019 $21,322 $138 $48–$462 $163
2020 $37,122 $79 $26–$262 $114
2021 $59,587 $119 $37–$358 $132
2022 $13,101 $139 $43–$424 $149
2023 $0 $167 $57–$473 $160
2024 $0 $168 $56–$541 $164
2025 $0 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Janssen Biotech, Inc. $88,121 116 payments
  2. Astellas Pharma US Inc $19,084 28 payments
  3. Pfizer Inc. $13,904 21 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $3,521 9 payments
  5. Novocure Inc. $2,790 7 payments
  6. AstraZeneca Pharmaceuticals LP $2,225 2 payments
  7. Dendreon Pharmaceuticals LLC $190 8 payments
  8. Regeneron Healthcare Solutions, Inc. $183 6 payments
  9. Boston Scientific Corporation $179 3 payments
  10. Foundation Medicine, Inc. $178 5 payments
  11. Other $757 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $96,860 66 payments
  2. Consulting Fee $19,695 10 payments
  3. Travel and Lodging $9,999 24 payments
  4. Food and Beverage $4,490 124 payments
  5. Education $88 3 payments
Products named General payments · program years 2019–2022
  1. ERLEADA $88,133 117 payments
  2. XTANDI $30,012 47 payments
  3. Xofigo $3,467 6 payments
  4. ORGOVYX $2,975 2 payments
  5. Optune $2,523 2 payments
  6. LYNPARZA $2,225 2 payments
  7. Oncology $242 4 payments
  8. PROVENGE $190 8 payments
  9. LIBTAYO $183 6 payments
  10. FOUNDATIONONE CDX $178 5 payments
  11. Other $1,864 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record